What is repaglinide?
Repaglinide belongs to a group of drugs known as meglitinides, often used to treat diabetes 2. Drugs are usually effective only in patients with high blood glucose levels due to acquired, environmental and genetic factors that cause insulin secretion defect or insulin resistance. Anti-diabetic drugs can be used separately or in conjunction with other oral agents along with the right diet and exercise. As with all drugs, repaglinide has the potential for adverse effects from mild to serious. Other names for antidiabetic drugs include Gluconorm®, Novonorm® and Prandia®.
In addition to hereditary factors, people who have a sedentary lifestyle or unhealthy eating habits usually become overweight or obese, which can cause defective insulin secretion. This physical condition can also cause insulin resistance as oily cells prevent the opening of chemicals that allow glucose to enter. For this reason, providers ZDRavot care generally suggests the right diet and exercise when trying to check high blood sugar levels. Repaglinide stimulates beta cells of pancreatic islands to secrete insulin by closing of potassium channels. Inhibition of potassium increases the inflow of calcium and this action initiates insulin secretion.
blood levels usually culminate about an hour after administration. Due to the rapidly acting nature of the repaglinide, the dosage is usually dependent on the amount of food ingested with each meal and the number of meals consumed in 24 hours. Increased foods produce elevated blood glucose levels, which requires increased production levels and insulin secretion. The advantage of this type of fast action includes less hypoglycaemic episodes, but individuals could be subject to more frequent monitoring of blood sugar levels.
drugs are contraindicated for breastfeeding or those that experience ketoacidosis. Persons canUp to serious reactions if they use repaglinide in the diagnosis of non -functional dysfunctional kidneys, liver, kidneys or pituitary gland. The oral antidiabetic agent is also not recommended in patients with severe infections. Repaglinide with other drugs that bind with proteins could cause an increased risk of developing hypoglycaemia. Some of these drugs include non -steroidal anti -inflammatory substances, anticoagulants and beta blockers.
Increased number of hypoglycaemic episodes may also occur in repaglinide in conjunction with antifungal, fluoroquinolone and macrolide antibiotics. The common adverse effects associated with drugs include hypoglycaemia, abdominal discomfort exposed to nausea or diarrhea and the possibility of developing upper respiratory tract infection. Among the more serious adverse effects are chest pain or difficulty breathing. Individuals allergic to medicines or some of the formula components may occur symptoms from mild skin reactions consisting of redness, itching and hives to anaphylaxis.